Skip to main content
Faes Farma S.A. logo

Faes Farma S.A. — Investor Relations & Filings

Ticker · FAE ISIN · ES0134950F36 LEI · 959800FXZQY7U3P1G969 MC Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2021-12-23 Director's Dealing
Country ES Spain
Listing MC FAE

About Faes Farma S.A.

https://faesfarma.com/en/

Faes Farma S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products, healthcare solutions, and animal nutrition products. The company's pharmaceutical division develops treatments for conditions in therapeutic areas including allergy, gastroenterology, and immunology, with key proprietary molecules such as Bilastine, a leading antihistamine, and Calcifediol for Vitamin D deficiency. The animal nutrition business provides nutritional solutions and supplements for sustainable animal production. A core focus of the company is its investment in R&D to develop novel molecules and health solutions for its global markets.

Recent filings

Filing Released Lang Actions
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM". This form explicitly details transactions (Compra/Buy) made by a director (MARIANO UCAR ANGULO, PRESIDENTE) of the issuer (FAES FARMA, S.A.). This type of filing, reporting insider trading or director dealings, corresponds directly to the 'Director's Dealing' category.
2021-12-23 Spanish
Aprobación del dividendo flexible
Capital/Financing Update Classification · 98% confidence The document is a formal communication in Spanish, addressed to the 'COMISIÓN NACIONAL DEL MERCADO DE VALORES' (CNMV), labeled as a 'HECHO RELEVANTE' (Material Event). The core subject is the execution of a capital increase ('aumento de capital') funded by reserves, which is part of a flexible dividend program. It details the terms, conditions, and timeline for shareholders to choose between receiving new shares or cash equivalent for their dividend rights. This document provides comprehensive details about a corporate financing/capital structure event, including specific dates, formulas, and shareholder options. This aligns perfectly with the definition of a Capital/Financing Update (CAP). While it relates to a dividend, the primary focus is the mechanics of the capital increase itself, not just the dividend announcement (DIV). It is not a full annual report (10-K) or an interim report (IR), but a specific corporate action announcement.
2021-11-26 Spanish
Informe de negocio tercer trimestre 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Faes Farma Informe de negocio' for the third quarter of 2021. It contains detailed financial tables (income statement, revenue breakdown by region, and business unit performance), analysis of business trends, and forward-looking statements. It is a comprehensive report on the company's performance for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2021
2021-10-29 Spanish
Faes Farma licencia bilastina en Estados Unidos
Regulatory Filings Classification · 95% confidence The document is titled "INFORMACIÓN PRIVILEGIADA" (Privileged Information) and is addressed to the "COMISION NACIONAL DEL MERCADO DE VALORES" (National Securities Market Commission, the Spanish regulator). It details a significant licensing agreement for a key product (bilastina) in the US market, along with updates on regulatory approvals in Australia and planned filings in China. This type of material disclosure concerning major business developments, licensing deals, and significant market expansion, which is likely to affect the share price, falls under the category of mandatory disclosure of price-sensitive information. In the provided list, this content is best classified as a general regulatory announcement or privileged information disclosure. Since it is not a standard financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a specific, material announcement, the most appropriate general category for mandatory regulatory disclosures that don't fit elsewhere is 'Regulatory Filings' (RNS). However, given the nature of the content (a major licensing deal and strategic update), it is highly specific. If 'IP' (Investor Presentation) or 'MDA' (Management Reports) were about strategic updates, they might fit, but this is a formal regulatory communication. Since the document is a direct communication of material, non-financial-statement-related news to the regulator, RNS is the best fit as a catch-all for significant regulatory disclosures not covered by other specific codes. The document length (4311 chars) is substantial enough that it is the report itself, not just an announcement of a report (RPA).
2021-09-20 Spanish
Composición de las Comisiones
Board/Management Information Classification · 99% confidence The document is a formal communication ('OTRA INFORMACION RELEVANTE') addressed to the Spanish National Securities Market Commission ('COMISION NACIONAL DEL MERCADO DE VALORES'). The content details unanimous resolutions passed by the Board of Directors regarding appointments to two key internal committees: the Audit and Compliance Committee and the Appointments and Remuneration Committee. This involves changes in the composition of board-related committees, which falls under the scope of Board/Management Information, specifically concerning governance structure and director roles. This aligns best with the 'Board/Management Information' category (MANG). The document is short and announces decisions made by the Board, not a general regulatory filing (RNS) or a specific remuneration report (DEF 14A).
2021-09-16 Spanish
Informe de negocio de primer semestre 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Faes Farma Informe de negocio Primer semestre 2021' (Business Report First Half 2021). It contains detailed financial statements (income statement, EBITDA, EBIT, etc.), analysis of business segments (Iberia, LATAM, Licensing, Animal Health), and forward-looking statements for the fiscal year. It is a comprehensive report covering a period shorter than a full fiscal year (H1 2021) and includes substantive financial data and management analysis, fitting the definition of an Interim/Quarterly Report. H2 2021
2021-07-28 Spanish

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.